Robust Association Between Changes in Coronary Flow Capacity Following Percutaneous Coronary Intervention and

Rikuta Hamaya1,2, Taishi Yonetsu3, Kodai Sayama4

  • 1Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.

Insights

Changes in coronary flow capacity (CFC) after percutaneous coronary intervention (PCI) predict lower risk of target vessel failure in chronic coronary syndrome patients. Pre-PCI CFC status largely determines these beneficial changes.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Physiology

Background:

  • Coronary flow capacity (CFC) is a key physiological marker for assessing myocardial ischemia.
  • Its role in guiding percutaneous coronary intervention (PCI) is recognized, but changes in CFC post-PCI remain understudied.
  • Understanding these changes is crucial for optimizing PCI strategies.

Purpose of the Study:

  • To investigate the determinants of delta CFC, the change in CFC status after PCI.
  • To evaluate the prognostic significance of delta CFC for clinical outcomes.
  • To explore the relationship between pre-PCI CFC status and post-PCI changes.

Main Methods:

  • Analysis of a single-center registry including 450 patients with chronic coronary syndrome (CCS).
  • Patients underwent fractional flow reserve (FFR)-guided PCI with pre- and post-PCI invasive coronary physiological assessments.
  • Thermodilution-derived CFC categories were used to assess changes and their association with target vessel failure (TVF).

Main Results:

  • A significant inverse association was found between improvement in CFC categories and the risk of incident TVF.
  • Each one-category improvement in CFC status post-PCI was associated with a 39% reduction in TVF hazard after adjustment.
  • Pre-PCI CFC status was a major predictor of post-PCI CFC changes.

Conclusions:

  • Changes in CFC following PCI are associated with reduced risk of TVF in CCS patients.
  • These findings suggest a mechanistic link between PCI, improved coronary physiology, and better vessel-oriented outcomes.
  • Delta CFC provides valuable prognostic information and may refine PCI decision-making.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
27
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
43
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
30
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
32
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
792